This signaling pathway is activated in more than 90% of cases of colorectal cancer (CRC), mainly because of a loss‐of‐function mutation or deletion of APC, partially an activating mutation in CTNNB1, or a loss‐of‐function mutation in AXIN1/2.3, 4. This evidence concerns the gene CTNNB1 and colorectal carcinoma.